◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › IDYA

IDEAYA Biosciences, Inc. (IDYA) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-09

IDEAYA Biosciences, Inc. (IDYA) operates in the Biotechnology industry and is headquartered in South San Francisco, United States with about 145 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, IDYA reported $219M in revenue and ($114M) in net income.

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.

Interactive charts & full statements → Open the IDYA valuation workbench →

IDYA Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$219M$7M$23M$51M
Operating Income (EBIT)($159M)($327M)($134M)($62M)
Net Income($114M)($274M)($113M)($59M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IDYA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$7M$11M$208M$0M$0M
Operating Income (EBIT)($108M)($95M)$108M($89M)($84M)
Net Income($98M)($83M)$119M($78M)($72M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IDYA Free Cash Flow History

IDYA Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$1.1B$1.1B$649M$388M
Total Liabilities$86M$65M$28M$38M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IDYA viewer.

Other Companies in Biotechnology

← IDXXAll stocksIEAG →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.